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Four thousand patients were registered by the Edinburgh Lung Cancer Group in 1981-1987; 9.5% had 
adenocarcinoma. Of these, 102 patients with pathological confirmation of the diagnosis, presenting to one 
hospital group in Edinburgh, were reviewed. Two cases were excluded after case note review. Of the remaining 
100, 64 were male and 36 were female, with a mean age of 73 years. The majority (89%) were smokers or 
ex-smokers, and 52% had a poor performance status (Karnofsky Index 10-70). Significantly, more adeno- 
carcinoma patients underwent surgery compared to other cell types (39 vs. 19%, P<O.Ol), and less were treated 
with radiotherapy (19 vs.31%). 
The 5-yr survival rate for the adenocarcinoma patients was 19 vs. 7% in the remainder of patients. Of 39 
patients referred for surgery, 37 had lung resections and their 5-yr survival rate was 42%. Post-operative 
staging showed 48% in Stage I, 27% in Stage II and 24% in Stage III. The majority of the long-term survivors 
had Stage I disease (64%). Forty-two percent of the patients received palliative therapy alone (all died within 
10 months). Ten percent of patients receiving radiotherapy survived for 5 yr. Review of these cases suggested 
two patterns of presentations: (1) patients with poor performance status, extensive disease and often pleural 
involvement (16%); and (2) patients with more localized disease (39%), many of whom were suitable for 
surgical resection with surprisingly good prognosis. 
Introduction 
Lung cancer is among the most common and lethal 
of all neoplastic diseases in the U.K., with over 
40 000 deaths each year (l-3). Scotland has probably 
the highest incidence of lung cancer in the world, 
with rates of 120 per 100 000 in men and 48 per 
100 000 in women (1,3). The Edinburgh Lung Cancer 
Group (ELCG), which was formed in 1980, com- 
prises chest physicians, oncologists, pathologists, 
radiologists, radiotherapists and thoracic surgeons 
(4). Members of the group serve a catchment popu- 
lation of about 950 000. The ELCG has conducted 
studies on various aspects of lung cancer over the 
past decade (5,6). 
Recent findings suggest that adenocarcinoma may 
be becoming a more prevalent type of bronchial 
carcinoma (7). In the U.S.A., the Veteran Admin- 
istration Lung Group (VALG), who have conducted 
clinical trials in all types of lung cancer for the past 
two decades, now consider adenocarcinoma to have 
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become the most common type of cancer of the lung 
(8). A comparable study has become increasingly 
important to review the current status of adenocarci- 
noma in Scotland in terms of both clinical features 
and survival. 
Patients and Methods 
Of over 4000 patients with lung cancer registered 
prospectively by the group during the years 1981- 
1987, 380 patients were diagnosed as having adeno- 
carcinoma (Table 1). A detailed study of the 102 
patients with adenocarcinoma presenting to physi- 
cians in one hospital group (City Hospital and Royal 
Infirmary, Edinburgh) was undertaken by the present 
authors. 
All the patients’ hospital records were reviewed 
and information was entered on a standardized pro- 
forma including the following details: age, sex, occu- 
pation, date of first symptom and date of diagnosis, 
smoking status, performance status according to the 
Karnofsky Index (9) evidence of metastasis, treat- 
ment given, date last seen and date of death. Findings 
on investigation were also noted which included 
bronchoscopy (in 67%) chest roentgenograms 
(postero-anterior and lateral), blood count and liver 
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Table I Cell types of all lung cancer patients presenting to Table 2 Clinical presentation of patients, according to 
the Edinburgh Lung Cancer Group (1981-1987) staging 
Cell type Number (patients) % Stage I Stage II Stage III Total 
(%I (“A) (“4 (%I 
Adenocarcinoma 380 9.5 
Small cell carcinoma 820 20.5 
Squamous cell carcinoma 1600 40.0 
Large cell carcinoma 560 14 
Other 640 16 
Total 4000 100 
Age 
function tests. Disease was staged according to the 
Tumour, Nodes and Metastasis (TNM) system (10) 
based on clinical and radiological features supple- 
mented by laboratory investigations. Post-operative 
staging included information from resected material. 
Normal mediastinal glands were not sampled 
routinely. 
<70 11 5 26 42 
>70 9 8 41 58 
Sex 
Male 15 8 41 64 
Female 5 5 26 36 
Karnofsky status 
l&70% 3 2 61 67 
80-100% 17 11 6 34 
Smoking status 
Smokers 20 13 57 90 
Non-smokers 0 0 10 10 
breast and kidney respectively, and were excluded 
from subsequent analysis. 
The diagnosis of adenocarcinoma was based on 
positive histopathological and/or cytological appear- 
ances. Most histopathologic reports were provided 
by the groups’ two senior pathologists using agreed 
criteria based on a revised and updated version of the 
World Health Organisation Classification (7). To 
confirm the histological results, 20 of the original 
histological slides were selected randomly and 
re-examined by one of the authors (DL). Although 
routinely subjected to a variety of audits and quality 
controls, slides with a cell type other than adenocar- 
cinema were not reviewed for this study. The form of 
treatment chosen for each patient was also noted: 
surgery, radiotherapy, chemotherapy or symptomatic 
palliative treatment alone. 
SEX AND AGE (TABLE 2) 
Sixty-four percent were male and 36% were female 
compared with 72% and 28% in the remaining 3900 
lung cancer patients. At the time of diagnosis, 4% of 
patients were aged under 50 years, 6% were aged 
50-59 years, 31% were aged 60-69 years, and 59% 
were aged 70 years and above. The median age was 
73.2 years (range 40-95) 71% were current smokers, 
18% were ex-smokers, and 11% were life-long non- 
smokers. Twenty-five percent of the females were 
non-smokers in this series. 
CLINICAL PRESENTATIONS 
Survival data was obtained from follow-up 
patients’ records along with information supplied by 
the Cancer Registry for South-east Scotland (11). 
Information for patients who had died and could not 
be traced from the above records was obtained from 
the Office of Registrar General of Scotland in 
Edinburgh. The actuarial survival in different sub- 
groups was compared by the life table method of Lee 
and Desu offered by the SPSSX Programme (12). 
Results 
Sixty-seven percent of the patients had a poor 
performance status achieving lo-70% using the 
Karnofsky Index (9). In contrast, 30 of the 37 
patients (81%) treated surgically had a Karnofsky 
performance status of 80% and above (Table 2). 
Roentgenographic appearances of the chest were 
normal in 11% of patients and showed a right-sided 
involvement in 52% of patients. Thirty-seven percent 
of patients showed left-sided involvement. Twenty- 
one percent of patients had a pleural effusion, 28% 
had a mass and 40% had a consolidation. Fibre-optic 
bronchoscopy was performed on 67% of the patients 
of which 36% (24 patients) had an entirely normal 
bronchoscopy. 
PATIENT CHARACTERISTICS 
A total of 102 patients who presented to physicians 
at the Royal Infirmary and City Hospital, Edinburgh 
with an initial diagnosis of adenocarcinoma of the 
lung were included in the study. On review, two cases 
proved to have extra-thoracic primary tumours in the 
STAGING AND DIAGNOSIS 
Initial disease staging according to the TNM 
classification (10) showed 20% of patients had Stage I 
disease, 13% had Stage II disease, and 67% of 
patients had Stage III disease. Post-operative staging 
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Table 3 Treatment selected for 100 patients, according to 
stage 
Stage I Stage II Stage III Total 
(“h) WI WI WI 
Palliative 0 0 42 42 
Radiotherapy 2 2 15 19 
Surgical 18 11 10 39 
Total 20 13 61 
was done in 37 resected patients according to the 
American Joint Committee for Cancer Staging 
Criteria (13). Pathological diagnosis was based on 
histological confirmation of biopsy specimen in 52% 
of patients, cytological confirmation of sputum, 
pleural fluid or bronchial washings in 14% of patients, 
and both histology and cytology in 34% of patients. 
Thirty-nine percent of patients showed evidence of 
metastasis at various sites including lymph nodes, 
bone, brain and liver. Brain metastasis was confirmed 
by CT scan in 9% of patients, 19% had bone met- 
astasis demonstrated by bone scan, and 7% had 
liver metastasis on the basis of a liver ultrasound. 
Metastasis was most common at presentation in 
patients receiving radiotherapy and palliative treat- 
ment (30 of 61 patients). 
THERAPY 
Of 100 patients, 19 patients had radiotherapy and 
42 patients had palliative treatment. Thirty-nine 
patients were referred for surgery, 37 of which had 
lung resection (Table 3). At thoracotomy, two 
patients were found to have extensive involvement 
and were therefore inoperable. Thus, significantly 
more patients with adenocarcinoma underwent sur- 
gery when compared with all other lung cancer 
patients (39% vs. 19%, P<O.OOl). Correspondingly, 
fewer patients were treated with radiotherapy (19% 
VS. 31%, P<O.Ol), while 42% (VS. 38%) received 
symptomatic palliative treatment alone. 
FIVE-YEAR SURVIVAL 
The 5-yr survival rate for the 100 patients with 
adenocarcinoma (Figs 1 and 2) was 19%, significantly 
more than the 7% in all other lung cancer patients 
(WO.001). Forty-two percent of patients survived 
5 yr or more after successful surgical resection of the 
tumour. Thirty of 37 surgical patients were male 
(78%) and their 5-yr survival was significantly worse 
than the seven females (41 vs. 87%, WO.01). Five- 
year survival in the 100 adenocarcinoma patients 
according to the TNM staging (10) was 35% in Stage 
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Fig. I Survival in adenocarcinoma. 0, all patients; 
0, surgery; a, radiotherapy; A, palliative treatment only. 
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Fig. 2 Five-year survival: All patients 
Table 4 Five-year survival according to TNM staging 
All patients 
(“/I 
Surgical patients 
WI 
Stage I 35.1 72 
Stage II 22 70 
Stage III 1 12 
I and 20% in Stage II patients (Table 4). Two of 
the 39 patients were found to have inoperable cancer 
at the time of surgery and therefore underwent 
thoracotomy alone; their survival was 96 and 80 
days, respectively. The 5-yr survival rate for the 
surgically resected patients were remarkable with 
72% in Stage I, 70% in Stage II and 12% in Stage III 
(Table 4, Fig. 3). 
Discussion 
This study describes current clinical presentation, 
management and outcome of lung adenocarcinoma. 
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The series comes from a large unselected group of 
patients .with lung cancer arising from a catchment 
population of about one million covering South-east 
Scotland (6,ll). The findings have particular rel- 
evance as Scotland has the highest incidence of lung 
cancer in the world (1,6). All patients were seen in 
one hospital group in Edinburgh by members of the 
Edinburgh Lung Cancer Group. Previous studies 
suggest that 83% of all patients with lung cancer in 
the catchment area are seen by members of the group 
(5). These data, therefore, reflect routine clinical 
practice in South-east Scotland and are probably 
representative of practice elsewhere in the U.K. 
Most cases of lung adenocarcinoma occur in 
smokers. Only 11% of these patients were life-long 
non-smokers which agrees with previous series 
(14,15). Although the overall prevalence of smoking 
is slowly falling in the U.K., this fall is much slower in 
women. 
Prevalence of adenocarcinoma is apparently over- 
taking other histological cell types in men (4,16,17) 
and women (18-20). Indeed, in the U.S.A., the inci- 
dence of adenocarcinoma in women has apparently 
almost doubled in 4 yr from 18% (1981-1984) to 36% 
(1981-1988) (10). 
Accurate staging of lung cancer has always been 
seen to be a hallmark in estimating progress, evalu- 
ating therapy and comparing data on cancer 
research. In this study, clinico-radiological staging 
was made according to TNM classification and the 
5-yr survival according to stages is shown in Table 4. 
Interestingly, 39% of the patients in this series were 
suitable for surgery; this was comparable to 32% in a 
recent American series (10). More accurate post- 
operative staging was obviously possible in resected 
patients, using the criteria of WHO and the American 
Joint Committee for Cancer Staging. 
However, difficulties in standardizing the criteria 
for histological cell typing especially in adenocarci- 
noma, are now well recognized (7). Furthermore, it is 
often difficult to differentiate primary from secondary 
tumours based on clinical and histological criteria. In 
this series, 15% of patients produced problems as cell 
typing was based on cytological specimens alone 
(sputum, pleural fluid or BAL fluid). Although sub- 
typing was not done in this series, it may have 
significant prognostic value. In a study by Sorensen 
et al. (21), bronchoalveolar carcinoma had the 
best prognosis, and solid carcinoma with mucus 
formation had the worst prognosis. Prognosis 
was intermediate for alveolar and papillary adeno- 
carcinoma. 
The overall 5-yr survival of the patients with 
adenocarcinoma in this series was 19%, slightly better 
Stage I Stage II Stage III 
Stage of disease 
Fig. 3 Five-year survival: surgical patients. 
than earlier series (22,23). Most patients with Stage 
III disease received palliative treatment. 
Those treated by surgical resection had a 5-yr 
survival of 42% (Fig. 1) which is encouraging and 
echoes the experience of most previous series (18, 22, 
23) except Rubenstein et al. (24). The 18 surgical 
patients with Stage I disease appeared to have a 
particularly good 5-yr survival (72%) (Fig. 3). This is 
similar to the findings by Naruke et al. (13) and 
emphasizes the prognostic value of perioperative 
staging (25). However, survival of patients with 
adenocarcinoma given non-surgical treatment was 
very poor as in other cell types and in many previous 
series (4,22,25,26). 
Three potentially useful clinical categories of 
patients emerged from analysis of this series of 
patients with adenocarcinoma. Approximately one- 
fifth of the patients presented with poor performance 
status, extensive disease and often pleural involve- 
ment (21%). These had a very poor prognosis 
(median survival 10 months). Two-fifths of patients 
presented with more localized disease, often Stage I 
or II, and good performance status. Many were 
suitable for resection with a surprisingly good 
prognosis (5-yr survival 42%). The remaining two- 
fifths of patients fell in between with an intermediate 
prognosis. 
This study thus confirms that early staging, cell 
typing and surgical resection, where possible, are 
often worthwhile in the management of patients with 
adenocarcinoma of the lung. 
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